CA
CTMX icon

Cliff Asness’s CytomX Therapeutics CTMX Stock Holding History

Cliff Asness’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Buy
+42,014
New +$160K ﹤0.01% 3826
2022
Q3 		– Sell
-391,860
Closed -$717K – 2225
2022
Q2 		$717K Buy
+391,860
New +$750K ﹤0.01% 1545
2021
Q4 		– Sell
-17,486
Closed -$89K – 2213
2021
Q3 		$89K Sell
17,486
-116,799
-87% -$625K ﹤0.01% 2206
2021
Q2 		$850K Buy
134,285
+33,277
+33% +$259K ﹤0.01% 1656
2021
Q1 		$781K Sell
101,008
-22,921
-18% -$181K ﹤0.01% 1660
2020
Q4 		$812K Buy
123,929
+1,937
+2% +$13.8K ﹤0.01% 1594
2020
Q3 		$811K Sell
121,992
-68,333
-36% -$507K ﹤0.01% 1528
2020
Q2 		$1.58M Buy
190,325
+49,986
+36% +$464K ﹤0.01% 1274
2020
Q1 		$1.08M Buy
140,339
+8,781
+7% +$61.2K ﹤0.01% 1317
2019
Q4 		$1.09M Buy
131,558
+76,900
+141% +$519K ﹤0.01% 1481
2019
Q3 		$403K Buy
54,658
+16,201
+42% +$160K ﹤0.01% 1824
2019
Q2 		$431K Buy
38,457
+16,356
+74% +$171K ﹤0.01% 1778
2019
Q1 		$238K Buy
22,101
+3,482
+19% +$51.5K ﹤0.01% 2037
2018
Q4 		$281K Sell
18,619
-13,871
-43% -$206K ﹤0.01% 1984
2018
Q3 		$601K Sell
32,490
-8,723
-21% -$199K ﹤0.01% 1888
2018
Q2 		$942K Sell
41,213
-4,499
-10% -$115K ﹤0.01% 1744
2018
Q1 		$1.3M Sell
45,712
-49,675
-52% -$1.42M ﹤0.01% 1562
2017
Q4 		$2.01M Buy
95,387
+42,751
+81% +$886K ﹤0.01% 1379
2017
Q3 		$956K Buy
52,636
+38,925
+284% +$607K ﹤0.01% 1697
2017
Q2 		$213K Buy
+13,711
New +$207K ﹤0.01% 2114

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Cliff Asness's CTMX Position: Q2 2026 in Review

Cliff Asness opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 42,014 shares worth $158K. The stake represents ﹤0.01% of the portfolio and ranks #3826 among its holdings. This is a return to the name: Cliff Asness previously reported a position in CTMX as recently as Q2 2022.

Cliff Asness first reported a position in CTMX in Q2 2017 and has held it in 20 quarters since. The position peaked at $2.01M in Q4 2017. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Cliff Asness held 42,014 shares of CytomX Therapeutics worth $158K as of Q2 2026.
  • CytomX Therapeutics was a new Cliff Asness position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3826 holding.
  • Cliff Asness first reported a position in CytomX Therapeutics in Q2 2017 and has held it in 20 quarters since.
  • Cliff Asness's CytomX Therapeutics position peaked at $2.01M in Q4 2017.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.